ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO423

GDF-15 and FGF-23 Are Associated with Mortality in Type 2 Diabetic Patients with Microalbuminuria

Session Information

Category: Chronic Kidney Disease (Non-Dialysis)

  • 301 CKD: Risk Factors for Incidence and Progression


  • Frimodt-møller, Marie, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Von Scholten, Bernt Johan, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Reinhard, Henrik, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Hansen, Tine, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Persson, Frederik, Steno Diabetes Center Copenhagen, Gentofte, Denmark
  • Parving, Hans-Henrik, Rigshospitalet, Copenhagen, Denmark
  • Rossing, Peter, Steno Diabetes Center Copenhagen, Gentofte, Denmark

We evaluated growth differentiation factor 15 (GDF-15) and fibroblast growth factor 23 (FGF23) reflecting different aspects of renal pathophysiology as determinants of decline in estimated glomerular filtration rate (eGFR), incident cardiovascular disease (CVD) and all-cause mortality in patients with type 2 diabetes (T2D) and microalbuminuria, but without clinical coronary artery disease


Prospective study including 200 patients. GDF-15 and FGF23 were measured at baseline. Adjusted Cox models included sex, age, LDL cholesterol, smoking, HbA1c, creatinine, systolic blood pressure urine albumin excretion rate (UAER) and for FGF23 also 25(OH)vitamin D . Main outcome measures: A decline in eGFR of >30%, at any time point during follow-up was the predefined endpoint of CKD progression. Hazard ratios (HR) are provided per 1 SD increment of log-transformed values of the biomarkers.


Patients were (± SD) 59 ± 9 years old, eGFR 91.1 ± 18.3 ml/min/1.73m2 and UAER (IQR) 103 (39–230) mg/24-h. During a median 6.1 years follow-up, there were 40 incident CVD events, 26 deaths and a total of 42 patients reached the renal endpoint after 4.9 years (median). Higher GDF-15 was a determinant of decline in eGFR >30% in unadjusted (HR (95% CI) 1.7 (1.3-2.4); p=0.001) and adjusted (HR 1.7 (1.1-2.5); p=0.018) models, a predictor of CVD in the unadjusted model (HR 1.4 (1.0-1.9); p=0.034) and of all-cause mortality in unadjusted (HR 1.8 (1.3-2.6); p<0.001) and adjusted (HR 1.9 (1.2-2.9); p=0.003) models. Higher FGF-23 was associated with all-cause mortality in unadjusted (HR 1.5 (1.1-2.0); p=0.010) and adjusted (HR 1.6 (1.1-2.2); p=0.011) models.


In patients with T2D and microalbuminuria, GDF-15 was independently associated with decline in kidney function and all-cause mortality, and higher FGF23 was associated with all-cause mortality.